It’s the Holiday Season: Time for More Job Cuts in Pharma

Posted in BioBusiness, BioJobBuzz

While the holiday season (beginning on Thanksgiving) is supposed to be joyous, it is usually the time of year that many life sciences and other large corporations announce job cuts. As expected, two companies, Mylan and Lilly announced today that they will be cutting the size of their work forces and laying off employee.

Mylan, whose CEO was forced to appear before Congressional committees because of the company’s egregiously high price it was charging for EpiPens, announced that it may lay off of as many as 3,500 workers. The reason for the layoffs was to “reduce redundancy” that resulted from Mylan’s $5.3 billion acquisition of Abbott Laboratories generic drug business, the $7 billion it paid to purchase the Swedish drugmaker Meda and the $1.0 billion for several topical skin medications from Renaissance Holdings. The layoffs will purportedly impact less than 10% of Mylan’s global workforce and help to cut costs and refocus operations at the generic drug manufacturer.

Likewise, troubled pharmaceutical manufacturer Lilly, whose CEO abruptly retired earlier this year announced that it was trimming its US pharmaceutical sales force. The announced cuts were related to the recent Phase 3 failure of the company’s Alzheimer’s project solanezumab. A company spokesperson did not disclose the number of sales representative who would lose their jobs.

Finally, this past September, the Danish company  Novo Nordisk, a world leader in the diabetes market, announced it would layoff 1,000 employees worldwide to cut costs and focus it efforts on developing “truly innovative” diabetes products.  Meanwhile, behind the scenes, speculation suggests that the layoffs are in response to payer pressures that are being brought to bear in the US, the company’s largest market.  Many of the cuts are expected in R&D where innovation has been lacking according to company executives.

Although these jobs cuts are taking place, the good news is that these workforce reductions are smaller than those announced in holiday seasons past!

Until next time

Good Luck and Good Job Hunting


It’s Layoff Season

Posted in BioBusiness

Yes–it is that time of year again–layoff season!  To that point, Amgen announced today that it was laying off an additional 1,200 jobs above the 2,900 the company announced it would layoff this past July.   Together, these layoffs represent about 20% of Amgen’s global workforce.  Amgen joins other life sciences companies including Novartis, Sanofi, Pfizer, AstraZeneca and others that have announced layoffs in 2014.

Companies like to announce layoffs in the Fall, to let employees who may be affected by the downsizing to not expect their bonuses this year (which are typically paid at years end).  While this is strictly business, it does kind of put a damper on holiday season joy.  And, because corporations are considered to be “people” –at least according to the US Supreme Court–they ought to show a little more sensitivity and compassion when announcing downsizing and layoffs before the holiday season.

Until next time…

Good Luck and Good Job Hunting!!!!!!!!!

Tis the Season…to Lose Your Job

Posted in BioJobBuzz

It is that time of year again….the layoff season.  Coincidentally, the end of the fiscal year frequently overlaps with the beginning of the holiday season.  This means that profits and losses for the past year have already been tabulated and new budgets have been crafted for the new fiscal year.  Not surprisingly, this is when management has the numbers and metrics it needs to determine upcoming staffing levels and whether or not layoffs are necessary.

To wit, yesterday Bristol Myers Squibb announced that it was laying off 75 workers in its R&D division to realign research priorities and cut costs. Also, Ariad said yesterday that it was reducing its US workforce  following its decision to temporarily suspend the marketing and commercial distribution of Iclusig® (ponatinib) in the U.S. Earlier this week, Novartis indicated that it would slash 500 jobs as it realigns its research efforts and attempts to control costs in both Europe and the US. And Shire announced that is was cutting 180 jobs in a UK facility. Finally, a little over a month ago, Merck announced that it would slash 8,500 R&D and marketing/sales positions worldwide.

Admittedly, getting laid off at the beginning or during the holiday season is a horrible thing. That said, since things are slowing down anyway, it gives persons who received pink slips sufficient time to beef up their resumes/CV and stash their year end bonuses into their IRA or checking account.

Tis the season….

Until next time…

Good Luck and Good Job Hunting!!!!!!!!

Valeant Pharmaceuticals to Eliminate 2850 Jobs

Posted in BioBusiness

Valeant Pharmaceuticals which recently purchased Bauch and Lomb for $8.7 billion today announced that it would eliminate approximately 2850 jobs (from its 19,000 person workforce) to save roughly $800 million over the next year and half.

According to a post on today’s Pharmalot blog:

Specifically, Valeant (VRX) will trim anywhere from 10 percent to 15 percent of its headcount, which numbers about 7,500 Valeant workers and between 11,000 and 12,000 Bausch & Lomb employees, a Valeant spokeswoman tells us. While corporate headquarters will remain in Laval, Quebec, and US headquarters and the new US eye health unit will stay in New Jersey, other facilities will be moved or closed.

While these cuts were not unexpected, it is still very difficult for those who will be losing their jobs to finally get the news.

There is likely to be more consolidation (and layoffs) in the life sciences sector as the biotech IPO craze continues to sizzle and China’s pharmaceutical industry begins to sputter.

Until next time….

Good Luck and Good Job Hunting!!!!

AbbVie to Fire Hundreds of Sales Reps

Posted in BioBusiness

AbbVie, the prescription drug spinoff of Abbott Laboratories revealed that it will be laying off several hundred cardiovascular sales reps. The fired workers will be a mix of full time sales personnel and contract workers.  The reason: generic encroachment of its cardiovascular drug franchises. Among those drugs is TriCor, which began facing generic competition in November. TriCor, along with related medication Trilipix, generated $1.1 billion in U.S. sales for AbbVie last year.. Niaspan, an extended-release version of a medicine to raise HDL also will face generic competition this year It sold $911 million for AbbVie in 2012

AbbVie is shifting its focus from primary care, such as drugs that treat a patient’s cholesterol, stroke or diabetes, to so-called specialty medications in areas of unmet health needs

AbbVie is jumping on the elimination of sales personnel bandwagon and joins Eli Lilly which late last week announced that it plans to dismiss hundreds of sales reps tomorrow, a spokesman confirms. The cuts may amount to 30 percent of the companywide sales force in its BioMedicines division, which includes the cardiovascular, neuroscience and Men’s health units Likewise, last Fall, NJ-based Bristol-Myers Squibb layed off 480 sales reps.

Based on the events of the past five years, it may not be a good idea to pursue a career as   a PhD-trained life scientist or a pharma sales rep!  Surprisingly, however, there is a growing need for biopharmaceutical/biotechnology sales reps….go figure!

Until next time…

Good Luck and Good Job Hunting!!!!!!!!!!

The Beat Goes On: More Layoffs at Life Science Companies

Posted in BioBusiness

Despite assurances that the economy is improving, many life sciences companies are still continuing to downsize.  According to the Pharmalot Blog New Jersey-based Mylan (a generic drug manufacturer)  is laying off nearly 120 people from its specialty offices in Basking Ridge, New Jersey, as part of a reorganization that will consolidate the specialty operation near its Pittsburgh headquarters. The cuts were disclosed in a state filing. A spokeswoman says some employees may relocate. The company is also closing a specialty pharmaceutical plant in Napa, California, later this year which will result in the lost of 270 additional jobs.

Likewise, Massachusetts-based Alkermes  plans to eliminate up to 130 jobs from a plant in Ireland  and, last week, Bristol-Myers Squibb (BMY) revealed that roughly 300 employees will lose their jobs as part of a plan to close the San Diego headquarters occupied by Amylin Pharmaceuticals, which was acquired by BMS last year.

Today, another New Jersey company Unigene that is investigating delivery of proteins and peptide-based drugs announced that it would cut up to 40%of it workforce as it reorganizes and tries to stay in business.

Finally, Swiss pharmaceutical giant Novartis said Tuesday it is consolidating its U.S.-based eye disease research projects in Cambridge, Mass., and closing the Novartis Institutes for BioMedical Research group on its Alcon Labs campus in Fort Worth. About 120 employees in Fort Worth were told Tuesday their jobs will end June 11, The employees will be allowed to apply for jobs in Cambridge as well as for other positions with Alcon. Novartis acquired Alcon, an ophthalmic drug company in 2011 and has been working for the past few years to consolidate all of Novartis’ eye research centers in one location in Fort Worth.  Alcon currently employees about 4,800 people.

While these layoffs are noteworthy, the size of these layoffs pale in comparison to the carnage that took place in the pharmaceutical industry over the past five years. According to Challenger Gray & Christmas, the recruiting and consulting firm more only 3,100 pharmaceutical employees lost their jobs this year. However, Ed Silverman, who writes the Pharmalot Blog mentioned in a post today that “there is industry speculation that Merck will undergo more job cuts.”

Although the industry is still shedding jobs, it is likely that the worst is over and that new job opportunities will emerge in the US and elsewhere over time.

Until next time…

Good Luck and Good Job Hunting!!!!!!!!

Here We Go Again: AstraZeneca to Cut 1,600 Jobs

Posted in BioBusiness

Just when many pharmaceutical employees’ anxiety about  job security was beginning to wane and things appeared to returning to “normal”, yesterday AstraZeneca (AZ) announced that it was slashing another 1,600 jobs.  While this was not unexpected, these new cuts add to the massive number of pharmaceutical employees who have lost their jobs over the past five years.

According to a press release, the cuts will help AZ to save roughly $190 million per year through 2016.  Most of the lost jobs will come from restructuring of AZ’s R& D operations in the UK, Sweden and the US.  To that end, all R&D activity will stop at AZ’s Alderley Park facility in Northwest England, the former hub of the company’s R&D activities.  Az’s MedImmune subsidiary in Gaithersburg, MD will be the main center for biotech drug R&D while AZ’s research center in MoeIndal Sweden will focus on small molecule discovery and development.

AZ’s new CEO Pascal Soriot said the reorganization and restructuring were necessary to better focus the company’s R&D efforts in the key therapy areas that include cancer, cardiovascular and metabolic disorders and respiratory and inflammatory diseases. The company will reduce its efforts in the areas of neuroscience and antiinfectives.

Interestingly, many of the job cuts were made so that the company can build a new $500 million all purpose facility in Cambridge, England to leverage the R&D and clinical talent in that part of Britain.  The new facility is expected to be built by 2016.  Looking on the bright side, many of the employees who just lost their jobs, can find new ones three years from now!

AstraZeneca has already reduced its global workforce by around 10,000 as it has struggled to cope with generic competition and disappointing progress in finding new drugs. It now employs a total of 51,700 around the world.

Don’t be surprised if other big pharma companies announce new job cuts in 2013.

Until next time…

Good Luck and Good Job Hunting!!!!!

New Report: High Job Anxiety Amongst Pharmaceutical Employees

Posted in BioEducation

A post today on the fabulous Pharmalot Blog revealed that a recent poll conducted by Pharma IQ showed that about 44 percent of all pharmaceutical employee respondents worry that they may become redundant (corporate speak for dispensable) over the next year or so. Further, 50 percent believe that staffing levels will remain the same for 2012 whereas 32 percent expect more layoffs to occur. Only 19 percent of the 535 pharma employees surveyed believe that hiring will increase this year.

Roughly 48 percent of respondents indicated that their groups/departments had not been downsized. However, 61% of respondents—who indicated that downsizing had taken place in their department— reported that their job functions were being performed by fewer numbers of employees. Twenty-five percent report that the job functions performed by layed off employees were outsourced. Of those, 10 percent said that the jobs were outsourced to emerging markets like China, India, and Brazil etc.

Interestingly, a whopping 71 percent believe that the massive layoffs that have taken place in pharma are a result of the recession. While this is what big pharma wants its layed off employees to believe, the bottom line is that the pharma industry began shedding jobs in 2001 mainly because of anticipated lost of patent expiry for many of its blockbusters and the lack of new molecular entities discovered by internal R&D programs not because of cash flow problems. To wit, a quick perusal of cash reserves indicates that most major pharmaceutical companies have roughly $5 to 35 billion in short term cash reserves. Simply put, the recession conveniently provided pharma execs with a legitimate excuse to downsize.

To be fair, big pharma companies will be losing substantial revenue streams because of loss of patent protection for blockbusters like Lipitor, Zyprexa, and Plavix etc. And, that some belt tightening may be in order to remain competitive. However, most pharma execs realized way back in the mid 2000s that they could no longer justify such large workforces in the wake of thinning pipelines and a much lower than expect ROI from internal R&D activities. Consequently, they had to layoff large numbers of R&D and sales employees to keep their stock prices stable and in some cases to retain their jobs. The fact that a majority of the current pharma employees surveyed believe that the massive pharma layoffs that have taken place over the last decade are a result of the recession suggests that these employees are still drinking the Kool-Aid freely offered by their employers.

There are a lot of other interesting statistics and tidbits in the report that may be worth a look. However, it is important to note, that it is highly unlikely that pharma will ever replace many of the US and European employees who lost their jobs. Recent moves made by most major pharmaceutical companies clearly indicate that they are betting on their growth in both R&D and sales to take place in emerging markets. Sadly, the future of the US life sciences workforce is no longer bright. In fact, it is quite dim!

Until next time…

Good Luck and Good Job Hunting!!!!!!!!!


AstraZeneca Sheds 7,300 Jobs

Posted in BioEducation

After announcing its quarterly earnings and a 24 percent increase in 2011 profits, AstraZeneca (AZ) today made public its decision to eliminate another 7,300 jobs. Earlier this week there was speculation that job cuts were likely but the exact numbers were not disclosed. 

The reasons given for the layoffs despite increased annual profits? Government spending cuts for healthcare and stiff generic competition for several of its blockbuster drugs including Seroquel XR (depression), Atacand (hypertension) Crestor (cholesterol-lowering) and Symbicort (asthma); all of which have lost or will be losing patent protection in the near future. According to a company press release generic competition cut revenues by $2.0 billion in 2011 whereas government price interventions cost the company another $1.0 billion. The announced job cuts are expected to save AZ $1.6 billion by 2014—great news for shareholders but not so much for the employees who are losing their jobs!

Most of the cuts will take place in R&D. To that end, the company will close its facility in Montreal and layoff staff at its Soedertaelje site in Sweden. Interestingly, the company plans on focusing more on neuroscience and intends to hire 40 to 50 scientists in its new Innovative Medicine unit which is partly based in Boston, MA and Cambridge in England.

While layoffs at AZ were expected, the size of the current layoff does not bode well for other pharmaceutical employees. It is becoming increasingly clear that big pharma companies are getting out of R&D and focusing their efforts on M&A and licensing deals to fill their thinning pipelines. Also, while shedding R&D and sales jobs in developed markets, big pharma companies are investing heavily in building facilities and hiring thousands of R&D and sales personnel in emerging markets. From my perspective, it appears that big pharma has consciously decided to abandon developed Western markets where sales growth is in the single digits in favor of emerging ones where double digit growth is expected for the next decade.

Until next time…

Good Luck and Good Job Hunting!!!!!!!!!


Monthly Pharma Layoff Report

Posted in BioEducation

Thing have been quiet in the pharma layoff space during 2012. I guess that is not so surprising since we are only one month into 2012. However, there was a post on yesterday’s Pharmalot blog which indicates pharma layoffs may resume in earnest over the next few weeks. 

According to the post, AstraZeneca (AZ) is poised to shed thousands of more jobs after the company announces it earnings later this week. As you may recall, AZ recently announced that it would lay off 400 employees at its US headquarters and eliminate another 1,150 jobs from its US sales force. Like other pharmaceutical companies, things have been tough for AZ as three of its blockbuster products Crestor (cholesterol lowering), Nexium (acid reflux) and Seroquel (antipsychotic) lose patent protection and face stiff generic competition.

The Pharmalot post also reported that:

“Between 2007 and 2009, AstraZeneca eliminated 12,600 positions, a move that saved $1.6 billion annually, although that figure rose to $2.4 billion by 2010. The cuts announced that year were designed to save $1.9 billion annually by 2014 It is not clear how much the drug maker hopes to save with still more cuts, but some $3 billion may be spent on a stock buyback to bolster shareholder confidence.”

It is important to note that the massive downsizing that has taken place in the pharma industry over the past decade has little to do with the recession and everything to do with the loss of blockbuster revenues due to generic encroachment. Put simply, most pharma companies grew too large too quickly and subsequently realized that could not sustain their vast infrastructures if the loss of blockbuster sales revenues could not be replaced by new products. To wit, if you look at the P&L statements of many pharmaceutical companies, most have $5 billon to $30 billion of readily-available cash reserves on hand to “play” with. Sadly, the downsizing that has taken place had little to do with the present and everything to do about the future profitability of big pharma companies.

Until next time…

Good Luck and Good Job Hunting!!!!!!